Skip to content
Open menu

Lung cancer

Lung cancer starts when cells in the bronchus or the actual lung tissue turn malignant.

Although the incidence of lung cancer has decreased in Finland, it is still one of the leading causes of cancer death among Finns. In Finnish men, only prostate cancer is a more common malignancy. Less than one third of new cases are diagnosed in women, but the percentage of women is rapidly increasing along with the increase in women smokers.

There are two main types of lung cancer: non-small cell lung carcinoma and small cell lung carcinoma. About 85% of all lung cancers are non-small cell carcinomas, and the remaining 15% are small cell lung carcinomas. There are specific treatments for each type.

Risk of disease:

Smoking is the best known and most studied cause of lung cancer: it causes 90% of all cases of lung cancer. Passive smoking (exposure to cigarette smoke produced by other people) also increases the risk. There are many factors in our working and living environments that increase the risk of lung cancer, such as arsenic, nickel and chromium compounds, radon and asbestos.


The symptoms of an early stage lung cancer are often very few and mild; distinct symptoms appear at a more advanced stage. Typical symptoms of lung cancer include:

  • cough
  • bloody sputum
  • shortness of breath
  • frequent inflammations of the lungs
  • general symptoms (loss of appetite, weakness, tiredness, episodes of fever and weight loss)

Sometimes the illness is not detected until it spreads to lymph nodes in the neck and these become swollen.


A chest x-ray examination is usually the most important initial examination when lung cancer is suspected. If sputum can be collected from the patient, it can be analysed for cancer cells. Sputum specimens are collected in a container and analysed under a microscope. However, this method is not very reliable. It is also possible to perform fine needle aspiration or core needle biopsies on the tumor in order to establish a diagnosis. This is done by bronchoscopy: the pharynx is anaesthetised, and the bronchoscope is led through the mouth and trachea into the lungs. Biopsy samples are then collected.

If a diagnosis cannot be established in this way, a tissue sample of the tumor can be collected through the skin using a thin needle. The location of the tumor in the lungs dictates whether this is possible. The needle is targeted to the precise location under ultrasound or CT guidance. The examination can feel unpleasant for the patient. Fortunately, it does not take very long. The tissue sample is analysed under a microscope for signs of cancer cells.

In order to ensure correct planning of treatment, it is important to determine whether the cancer is a non-small cell or small cell carcinoma. Staging is usually performed by a CT scan of the lungs. The scan helps to assess whether the tumor has spread to mediastinal lymph nodes between the lungs or to other parts of the lungs.


There are several possible treatments for lung cancer: surgery, radiotherapy, chemotherapy and other targeted pharmacological therapies. In addition to the cell type, the choice of treatment depends on the stage of the cancer, the patient’s age and gender and the presence of possible general symptoms (weight loss) before treatment.

Surgery is the primary treatment for non-small cell lung cancer. It is the only available curative treatment for lung cancer. The operation is demanding, and it is only possible if the patient’s physical condition is good enough and the cancer has been confirmed to be a non-small cell carcinoma and is localised. In small cell lung carcinomas, surgery is possible only in the event that the tumor is restricted to a sufficiently small area. Chemotherapy is the most important treatment for small cell lung cancers. Chemoradiotherapy (a combination of chemotherapy and radiotherapy) is effective in both types of lung cancer; it can hold back the progress of the disease, improve patients’ quality of life and prolong survival.

Read more

Verification of identification

Please be prepared to present an identity document when you register at the reception.

Read more

Investments in diagnostics, cancer treatment and services – Docrates Cancer Center published its 2023 annual review

In 2023, Docrates Cancer Center promoted its strategy by investing in larger facilities, developing services related to the early detection...

Customer infoletter 21, May 2024

Docrates Cancer Center becomes part of Mehiläinen through an acquisition signed on 16 May 2024. The transaction requires the approval...

Docrates Cancer Center becomes part of Mehiläinen

Docrates Cancer Center, which specialises in the diagnostics, treatment and monitoring of cancer, becomes part of Mehiläinen through an acquisition...

Why come to Docrates Cancer Center?

  • Top cancer experts and effective treatments without delay.
  • Individual care. You have your own care team - your doctor and your nurse.
  • Front line cancer treatment. Latest medical technology combined with proven expertise in cancer care.
  • Experience in treating international patients from over 60 countries. Multilingual personnel.
+358 10 773 2010

Contact us!

Mon-Thu 8:00-18:00, Fri 8:00-16:00